AUTL – autolus therapeutics plc - american depositary shares (US:NASDAQ)
Stock Stats
News
Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026 [Yahoo! Finance]
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics (NASDAQ:AUTL) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
Form SCHEDULE 13G/A Autolus Therapeutics Filed by: ARMISTICE CAPITAL, LLC
Form SCHEDULE 13G/A Autolus Therapeutics Filed by: MAK Capital Fund LP
Form 424B3 Autolus Therapeutics
Form 8-K Autolus Therapeutics For: Jan 21
Form 424B3 Autolus Therapeutics
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.